Sugi Predict

Sugi Predict / Compounds / SCHEMBL10043865

SCHEMBL10043865

SCHEMBL10043865

CCCC(C)C(=O)NC(=O)Nc1ccc(C)c(-c2cc3cnc(C)cc3n(C)c2=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.38
▸ RAF1 P04049 2/20 0.35
▸ BRAF P15056 2/20 0.35
▸ KRAS P01116 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ FGFR4 P22455 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ RAB9A P51151 3/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ ABL1 P00519 3/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KIT P10721 1/20 0.33
▸ PDGFRA P16234 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043858 0.89 SYK (0.40) SYKRAF1BRAFKRASFGFR1
SCHEMBL10043824 0.84 MAPT (0.42) SYKRAF1BRAFKRASFGFR1
SCHEMBL12400251 0.84 SYK (0.39) SYKRAF1BRAFKRASFGFR1
SCHEMBL10043829 0.84 SYK (0.41) SYKRAF1BRAFKRASFGFR1
SCHEMBL10043828 0.82 RAB9A (0.48) SYKRAF1BRAFKRASFGFR1
SCHEMBL10043835 0.82 HTR2A (0.43) SYKRAF1BRAFKRASFGFR1
SCHEMBL10043719 0.82 ALDH1A1 (0.46) SYKFGFR1SRCRAB9ACYP1A2
SCHEMBL10043857 0.81 POLB (0.45) SYKFGFR1SRCRAB9AMAPT
SCHEMBL10043871 0.81 ABL1 (0.46) HSD17B10ABL1
SCHEMBL854868 0.81 SYK (0.38) SYKRAF1BRAFKRASFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885RAF1 11/4885BRAF 36/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885RAF1 11/4885BRAF 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.